A conventional lender asks whether a company can repay a loan from its overall cash flow. Royalty-based capital asks a different question: how much will this specific product sell, for how long, and how reliable is the right to a share of those sales? That shift changes what matters in diligence.
This perspective walks through the main areas of product-level underwriting, the downside cases that deserve the most attention, and how the findings shape the structure of a transaction. It describes an approach, not any specific product or transaction.
A different question
Corporate credit focuses on the borrower: its revenue, margins, leverage, liquidity and management. Those factors still matter in royalty-based financing, but they are secondary. The primary asset is a stream of payments tied to the sales of one product, or a small number of products.
That narrower focus is an advantage. A company may be unprofitable because it is investing heavily in research, yet one of its approved products may have a clear sales history, durable protection and strong demand. Underwriting the product lets capital reach that value without requiring the whole company to look like a conventional borrower.
The product
The starting point is the product itself: its approval status, the strength of its clinical data, how it compares with existing and expected alternatives, and how physicians, patients and payers are likely to respond. For an approved product, actual sales history matters a great deal. For a late-stage product, the probability and timing of approval become central.
Approved and late-stage products call for different emphasis. With an approved product, the questions are about trajectory: how quickly sales are growing, which patient segments are driving demand, how refill and persistence rates look, and where the ceiling might be. The data exists, and the work is to interpret it correctly.
With a late-stage product, the first question is whether it will be approved at all, and on what label. Clinical results, the regulatory history of similar products and the quality of the sponsor's interactions with the FDA all inform that judgment. A narrower label than expected, a required risk management program or a delayed decision can change the commercial picture considerably even when approval comes.
Clinical data deserves a close reading, not a summary. How large and well designed were the pivotal trials? Were the results consistent across patient groups? What does the safety profile look like, and are there signals that could lead to label changes? A product with modest efficacy and a clean safety record can outperform a more effective product that physicians hesitate to prescribe.
Manufacturing and supply are part of the product, too. A single contract manufacturer, a complex biologic process or a scarce raw material can interrupt sales regardless of demand.
The market
Next comes the market: the size of the treatable population, pricing and reimbursement, the speed of adoption and the competitive landscape over the life of the royalty. A product can be scientifically excellent and still face a difficult commercial path if pricing or reimbursement is uncertain.
Reimbursement in the United States runs through a mix of government programs and commercial payers, and each has its own coverage process. Medicare drug price negotiation, introduced by the Inflation Reduction Act of 2022, adds another variable for products with significant Medicare exposure. Underwriting has to consider how pricing could change over the full term of the royalty, not only today.
Competition must be projected forward as well. A product that leads its category today may face new entrants with better dosing, a new mechanism or a lower price within a few years. Pipeline analysis of competitors is as important as analysis of the product itself.
Medical devices and diagnostics add their own considerations. Regulatory pathways differ from those for drugs, coverage and coding decisions can determine whether a test or device is used at all, and adoption often depends on hospital purchasing committees and clinical workflow as much as on physician preference. The underwriting disciplines are similar, but the evidence that matters is different.
The rights
Then there is the legal foundation: the patents that protect the product and when they expire, the terms of the license or royalty agreement, audit rights, and what happens if the product is sold, the licensee is acquired or a dispute arises.
The value of a royalty depends on the contract as much as on the product.
The value of a royalty depends on the contract as much as on the product. Market exclusivity can come from patents or from regulatory exclusivities, such as those for new chemical entities, orphan drugs and biologics, and the two do not always end at the same time. Generic and biosimilar challenges, including patent litigation under the Hatch-Waxman framework, can shorten the period of protection that a forecast assumes.
The agreement itself can raise or lower value. A clear net sales definition, robust audit rights, limits on royalty reductions and sensible change-of-control provisions all make a royalty more dependable. Gaps in any of them can turn a strong product into a weaker asset.
The commercial partner
Finally, because royalty holders rarely control how a product is sold, the capability and commitment of the company marketing it matter. A strong commercial partner can expand a product's reach. A distracted one can leave value on the table.
Useful signals include the size and focus of the sales organization, its experience in the therapeutic area, its relationships with payers and specialty pharmacies, and how important the product is to the company's overall strategy. A product that ranks low in a large portfolio may receive less attention than its potential deserves.
The agreement can help here. Commercially reasonable efforts clauses, reporting obligations and consent rights over a transfer of the product give the royalty holder some recourse. They cannot replace a capable partner, but they set expectations and create a record if performance falls short of what was promised.
Building the downside case
A base-case forecast is necessary, but the downside cases shape the transaction. Product-level underwriting should test what happens when the most plausible risks occur, alone and in combination.
- A slower launch or flatter adoption curve than the company projects.
- Earlier generic or biosimilar entry following a successful patent challenge.
- A new competitor that takes share or forces price concessions.
- Reimbursement changes, including government price negotiation or tighter payer coverage.
- A safety signal, label change or manufacturing disruption.
- A change of control that shifts the product's priority within a new owner's portfolio.
Structure is where diligence turns into protection.
Each scenario should be traced to its effect on payments over the full term. Structure is where diligence turns into protection. If the key risk is launch timing, milestone-contingent funding may fit. If it is a patent cliff, the payment profile can be weighted toward the protected years. If it is a change of control, a put right or acceleration provision can address it.
Common mistakes in product underwriting
One mistake is anchoring on the company's own forecast. Management projections are a starting point, but they are built to support the company's plans. Independent analysis of prescriber behavior, payer dynamics and competition often produces a different view.
Another is treating exclusivity dates as fixed. Patent challenges, settlement terms and regulatory decisions can move them. A third is reading the license or royalty agreement after the commercial work is done, when its terms should inform the forecast from the start.
For a company or royalty holder seeking capital, product-level underwriting has practical implications. Organized sales data, clean contracts, a clear patent and exclusivity map and a candid account of competitive risks shorten the process and improve the conversation. A counterparty who understands the product can offer structures that fit its actual risks rather than generic terms.
Diligence as one integrated view
These areas are often assessed by different specialists: scientists for the data, regulatory experts for the approval path, patent counsel for exclusivity, and commercial analysts for the forecast. The risk is that each produces a sound report that never connects to the others.
The most important insights usually sit at the boundaries. A safety finding affects the label, which affects the addressable population, which affects the forecast. A patent challenge affects the exclusivity date, which affects how much of the forecast is protected. Integrated diligence means one team holds all of those threads and carries each finding through to its effect on payments.
How Crucible approaches it
UpManagement Crucible is being built around this product-level discipline, with integrated diligence across science, clinical data, FDA and CMS regulation, patents and exclusivity, and commercial and pricing dynamics, and with risk-adjusted valuation that includes explicit downside cases. It is an investor and financier, not a drug developer, and draws on UpManagement's shared platform for finance, compliance, legal, technology and operations.
Crucible is a platform in formation. Its investment adviser registration and other approvals are not yet in place.
This article is for general information only. It is not an offer to sell, or a solicitation of an offer to buy, any security or investment product, and nothing on this site markets any investment.
Published by UpManagement. This article is general information about the sectors in which the UpManagement companies operate. It is not legal, tax, investment or compliance advice, and it is not an offer to sell or a solicitation of an offer to buy any security. Where a company is described as a platform in formation, its approvals are not yet in place.
